PMID- 25827934 OWN - NLM STAT- MEDLINE DCOM- 20150819 LR - 20230425 IS - 1349-7006 (Electronic) IS - 1347-9032 (Print) IS - 1347-9032 (Linking) VI - 106 IP - 6 DP - 2015 Jun TI - Correlation between the International Neuroblastoma Pathology Classification and genomic signature in neuroblastoma. PG - 766-771 LID - 10.1111/cas.12665 [doi] AB - The International Neuroblastoma Pathology Classification (INPC) has a prognostic impact that distinguishes two categories of neuroblastoma: favorable histology (FH) and unfavorable histology (UH). We analyzed 92 cases of neuroblastoma with the INPC evaluation and genomic grouping to investigate the correlation between the INPC and genomic signature, together with their prognostic significance. The correlation of UH tumor and partial gains and/or losses (GGP), as well as the correlation of FH tumor and whole gains and/or losses (GGW), was statistically significant. Both UH and GGP were late-onset (median age at diagnosis was 36 and 48 months, respectively) and had poor prognosis (overall survival rate [OS], 43.1% and 42.4%, respectively). In contrast, both FH and GGW were early-onset (median age at diagnosis, 4 and 9.5 months, respectively) and had favorable prognosis (OS, 88.6% and 87.1%, respectively). Unfavorable histology and GGP had significantly inferior OS compared to FH and GGW. Overall survival was not significantly different among the genomic groups in FH; however, it was inferior in UH with GGP. In UH with a single copy MYCN, genomic subgroups GGP2s (both 1p and 11q losses) and GGP3s (partial 11q loss but not 1p loss) indicated significantly poor prognosis compared to GGP4s (no partial 1p and 11q loss). As INPC and MYCN amplification were found to be the most powerful prognostic biological factors, they should be included with genomic grouping as treatment stratification for patients with UH and single copy of MYCN. CI - (c) 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association. FAU - Nakazawa, Atsuko AU - Nakazawa A AD - Department of Pathology, National Center for Child Health and Development, Tokyo, Japan. FAU - Haga, Chizuko AU - Haga C AD - Department of Pathology, National Center for Child Health and Development, Tokyo, Japan. FAU - Ohira, Miki AU - Ohira M AD - Laboratory of Cancer Genomics, Chiba Cancer Center Research Institute, Chiba, Japan. FAU - Okita, Hajime AU - Okita H AD - Department of Pathology, National Center for Child Health and Development, Tokyo, Japan. AD - Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan. FAU - Kamijo, Takehiko AU - Kamijo T AD - Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan. FAU - Nakagawara, Akira AU - Nakagawara A AD - Saga-ken Medical Center Koseikan, Saga, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150422 PL - England TA - Cancer Sci JT - Cancer science JID - 101168776 RN - 0 (MYCN protein, human) RN - 0 (N-Myc Proto-Oncogene Protein) RN - 0 (Nuclear Proteins) RN - 0 (Oncogene Proteins) SB - IM MH - Gene Amplification MH - Humans MH - N-Myc Proto-Oncogene Protein MH - Neuroblastoma/classification/genetics/mortality/*pathology MH - Nuclear Proteins/genetics MH - Oncogene Proteins/genetics PMC - PMC4471784 OTO - NOTNLM OT - Array comparative genomic hybridization OT - neuroblastoma OT - pathology OT - risk assessment OT - risk factors EDAT- 2015/04/02 06:00 MHDA- 2015/08/20 06:00 PMCR- 2015/06/01 CRDT- 2015/04/02 06:00 PHST- 2014/12/31 00:00 [received] PHST- 2015/03/25 00:00 [revised] PHST- 2015/03/26 00:00 [accepted] PHST- 2015/04/02 06:00 [entrez] PHST- 2015/04/02 06:00 [pubmed] PHST- 2015/08/20 06:00 [medline] PHST- 2015/06/01 00:00 [pmc-release] AID - 10.1111/cas.12665 [doi] PST - ppublish SO - Cancer Sci. 2015 Jun;106(6):766-771. doi: 10.1111/cas.12665. Epub 2015 Apr 22.